Bajaj Healthcare Limited
Established in the year 1993, Bajaj Healthcare Ltd is an estalished player in the Indian Pharmacuetical Industry and fastest growing mid-cap pharmaceutical companies in India.
What Bajaj files
- Others73
- Important20
- Updates17
- Board Meeting11
- Investor Meet7
- Dividend/Bonus4
Bajaj Healthcare will conduct its 33rd Annual General Meeting online. The Annual Report for FY2025-26 is accessible. Shareholders are urged to update KYC information and dematerialize physical securities for uninterrupted receipt of payments and communications.
Bajaj Healthcare reported 31% export contribution and no regulatory fines or product recalls. It increased renewable energy use and reduced water intensity, but saw a rise in total waste generated and employee turnover. Zero Liquid Discharge is now implemented at two units.
Bajaj Healthcare's Q1 FY27 revenue grew 11.3% to Rs. 165.6 Cr, with PAT up 15.8% to Rs. 13.7 Cr. Domestic API sales surged 27%. A key milestone for Cenobamate Tablets, a next-gen anti-seizure drug, was secured. An expanded R&D centre is now operational.
Bajaj Healthcare is selling an operational unit for up to ₹4.05 Cr to M/s Orchem Products. This unit contributed 0.54% to revenue and 0.74% to net worth, signaling a minor strategic asset sale.
Bajaj Healthcare reported FY26 revenue up 12.6% to Rs 611.03 Cr, driven by strong API exports and formulations. PAT from continuing operations grew 27.1% to Rs 54.56 Cr. Q4 faced API price erosion. The company raised Rs 52.7 Cr for growth and is advancing new CNS drugs.